PD 360324 / Pfizer - LARVOL DELTA

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (clinicaltrials.gov) - P1/2 | N=409 | Terminated | Sponsor: Pfizer | Phase classification: P1b/2 ➔ P1/2

Combination therapy • Metastases • Phase classification • Bladder Cancer • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • ALK • EGFR • ROS1

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (clinicaltrials.gov) - P1b/2 | N=405 | Terminated | Sponsor: Pfizer | Active, not recruiting ➔ Terminated; The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the Investigational treatments have been moved to a continuation study (NCT05059522)

Trial termination • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • ALK • CD8 • EGFR • ROS1

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (clinicaltrials.gov) - P1b/2 | N=398 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Apr 2022 ➔ Feb 2023 | Trial primary completion date: Apr 2022 ➔ Feb 2023

Combination therapy • IO biomarker • Trial completion date • Trial primary completion date • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • ALK • CD8 • EGFR • ROS1

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (clinicaltrials.gov) - P1b/2; N=398; Active, not recruiting; Sponsor: Pfizer; Trial completion date: Feb 2024 ➔ Apr 2022; Trial primary completion date: Feb 2024 ➔ Apr 2022

Clinical • Combination therapy • IO biomarker • Trial completion date • Trial primary completion date • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • ALK • CD8 • EGFR • ROS1

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (clinicaltrials.gov) - P1b/2; N=392; Active, not recruiting; Sponsor: Pfizer; Recruiting ➔ Active, not recruiting; N=620 ➔ 392

Clinical • Combination therapy • Enrollment change • Enrollment closed • IO biomarker • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • ALK • CD8 • EGFR • ROS1

JAVELIN Medleyt: A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (clinicaltrials.gov) - P1b/2; N=620; Recruiting; Sponsor: Pfizer; Trial completion date: Dec 2022 ➔ Feb 2024; Trial primary completion date: Dec 2022 ➔ Feb 2024

Clinical • Combination therapy • IO Biomarker • Trial completion date • Trial primary completion date • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • ALK • EGFR • ROS1

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (clinicaltrials.gov) - P1b/2; N=549; Recruiting; Sponsor: Pfizer; Trial primary completion date: Dec 2018 ➔ May 2020

Trial primary completion date • Biosimilar • Gastrointestinal Cancer • Head and Neck Cancer • Immunology • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Triple Negative Breast Cancer

Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer (clinicaltrials.gov) - P2; N=15; Not yet recruiting; Sponsor: M.D. Anderson Cancer Center; Trial completion date: Apr 2020 ➔ Apr 2021

Trial completion date • Biosimilar • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

JAVELIN Medleyt: A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (clinicaltrials.gov) - P1b/2; N=620; Recruiting; Sponsor: Pfizer; Trial completion date: Dec 2020 ➔ Dec 2022; Trial primary completion date: Dec 2020 ➔ Dec 2022

Clinical • Combination therapy • IO Biomarker • PD(L)-1 Biomarker • Trial completion date • Trial primary completion date

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: M.D. Anderson Cancer Center; N=15 ➔ 0; Trial completion date: Dec 2020 ➔ Feb 2019; Not yet recruiting ➔ Withdrawn; Trial primary completion date: Dec 2020 ➔ Feb 2019

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal

JAVELIN Medleyt: A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (clinicaltrials.gov) - P1b/2; N=560; Recruiting; Sponsor: Pfizer; Trial completion date: Jul 2020 ➔ Dec 2020; Trial primary completion date: Jul 2020 ➔ Dec 2020

Clinical • Combination therapy • IO Biomarker • PD(L)-1 Biomarker • Trial completion date • Trial primary completion date